Spring Bank discontinues hepatitis drug after patient death in trial
January 29, 2020 at 08:47 AM EST
Spring Bank Pharmaceuticals said on Wednesday it has discontinued the development of its experimental drug to treat chronic hepatitis B virus (HBV), following the death of a patient in a mid-stage trial.